Reviva Pharmaceuticals (NASDAQ:RVPH) Cut to “Hold” at D. Boral Capital

D. Boral Capital cut shares of Reviva Pharmaceuticals (NASDAQ:RVPH) from a buy rating to a hold rating in a research report released on Thursday morning, Marketbeat.com reports.

RVPH has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Thursday, January 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $2.00 target price on shares of Reviva Pharmaceuticals in a research report on Monday, January 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Reviva Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.33.

Reviva Pharmaceuticals Trading Down 15.5%

Shares of NASDAQ:RVPH opened at $0.18 on Thursday. The stock’s 50-day moving average price is $0.29 and its two-hundred day moving average price is $0.44. Reviva Pharmaceuticals has a 12-month low of $0.17 and a 12-month high of $1.24. The firm has a market cap of $20.55 million, a price-to-earnings ratio of -0.39 and a beta of 0.10.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after acquiring an additional 29,063 shares during the last quarter. NewEdge Advisors LLC acquired a new position in Reviva Pharmaceuticals in the first quarter worth $58,000. XTX Topco Ltd increased its stake in Reviva Pharmaceuticals by 63.6% during the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after purchasing an additional 63,893 shares during the last quarter. Lido Advisors LLC acquired a new stake in shares of Reviva Pharmaceuticals during the third quarter worth $37,000. Finally, Millennium Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after purchasing an additional 223,178 shares during the period. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.